Shares of ImmuPharma plc (LON:IMM – Get Free Report) shot up 16.2% on Thursday . The company traded as high as GBX 4.30 and last traded at GBX 4.30. Approximately 1,065,174 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 2,734,189 shares. The stock had previously closed at GBX 3.70.
ImmuPharma Price Performance
The stock’s fifty day moving average price is GBX 4.21 and its 200-day moving average price is GBX 5.46. The firm has a market cap of £26.83 million, a PE ratio of -11.62 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%. On average, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
